You're watching...
Credit Suisse Managing Director Catherine Arnold discusses whether ObamaCare will impact the pharmaceutical industry.
Also in this playlist...
Auto-advance: ON
Auto-advance
This transcript is automatically generated
Lets -- markets with Obama cast stalks and yes the pharma industry joining us now is Catherine Arnold Credit -- managing director.
And global head of pharmaceuticals -- and welcome -- the program history pickles Obama -- -- about implementation 2014.
Should I buy pharmaceutical -- going into obamacare.
You wanna buy pharmaceutical stocks -- -- -- -- by the -- monetary wanna buy them for the pipeline obamacare doesn't had a lot you might be surprised by bringing in 25 million lives.
Why isn't that big deal because those lives don't use a lot of drugs they only use about one prescription per month.
And the target -- -- attacks and the government's gonna want better pricing that's not -- -- But we are appointment -- -- I would do without issue for a -- Obama -- here comes you saying it's not a big boost for pharmaceutical stock that's right not it's just not that it's called big money maker of Obama doesn't doesn't drop to the bottom line and and meaningful way for these guys believe that our time okay.
Coming out of that you said will look at the pipeline that is not -- to -- them.
That's the drugs that the drug company has coming down the pike for the gonna hit the market in the future -- you say some of these stocks have a great pipeline -- -- -- -- industry has a great pipeline and there are some stocks were that's in the stock price and -- some stocks that aren't.
But the industry went through a big drought -- and now we have breakthroughs in many areas if for example.
If I could just -- does -- tell you tell you -- think cancer really sophisticated stuff happening in hepatitis.
We're almost seeing cure almost cure rates in some of the drugs that are in late stage development its way that I really -- okay hold it like I -- break -- down.
You say Kansas new arrivals on the drug market here they come.
Give me the name of the drug company that's got a big breakthrough in the cancer area.
Let me tell you Bristol-Myers has a an approach which is very sophisticated called -- on what it means basically gets your body to fight against his own cancer.
Which is different than what we used to do which is essentially -- -- against the two marks -- -- Bristol-Myers new approach.
And you like it Bristol-Myers Tuesday a very good story do you own it I do not OK Charles you wanted to get it you know I can't give openings on these big drug.
There's a long time ago in part for the problem -- pipelines and also.
Just because of the what the model in other words they -- all this this money they create these products and ultimately.
A generic version of its gonna go -- the window of opportunity seems so small it seems like the real excitement of the Big Bang has been and Biotech.
Now unfortunately good thanks take patients and it's hard -- -- -- have a real breakthrough and on the drug's side it is cyclical thing to.
As -- that's what you view yes you've seen a lot of years -- it hasn't been great.
We -- -- place for 80% of all prescriptions are generic now.
So we are close to the bottom in terms of the sort beating down of the generics against the brand and -- in new cycle on the product side.
So I would take another look.
At the drug industry for that reason I wanted to get back to hepatitis.
As the three Q all right so going out there given the name of the drug company and her in the treatment there are three drug companies that what one -- -- -- -- -- Biotech company Abbott and Bristol-Myers.
All have hepatitis treatments that we've seen peaks at their data.
Which is suggest over 90% of patients can be cured that's -- you.
Hewlett -- that's huge.
It was about 50% in and the standard of care that we have today it's -- think it's a very big deal will be getting more data on this year -- exciting you own Gilead.
I don't do not -- your future it Gilead Sciences -- -- Bristol on assets and that's the hepatitis people that's correct Bristol minds is the new treatment new approach for -- Merck is well has the new treatment new approach to cancer it's exciting yeah I mean it's it's very interesting to get real names real products last moment.
What about with teaching population alzheimer's and other dementia drugs -- this year has had it it's.
And somewhat controversial but I think we know more now -- alzheimer's thanks to at least program.
On for a truck console and -- amount.
It it it does appear that the information we've learned from that suggest positive outlook for alzheimer's.
-- and that's good for really that's good for -- that's good for Merck so Lilly alzheimer's in making that connection as well.
Correct me.
That was fascinating counts and on what will you come back I'd be happy value based in New York I am an awful -- unit.
-- -- -- -- thank you so much for joining me appreciate it alright and.
